Search results

Technologies 1

• Implantable Cancer Vaccine
  The Wyss Institute’s implantable, biodegradable cancer vaccine leverages immunotherapeutic methods and could one day help overcome melanoma, other cancers, infectious diseases, auto-immune diseases, as well as vaccinate against specific peptides, proteins, or antigens. The implant is a biodegradable polymer scaffold containing growth factors and components of each patient’s tumors. The technology was initially designed to...

Collaborations 1

• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 10

View all

• Research Spotlights
  
  Harvard “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awards first grant to Dana-Farber cancer immunologist Eric Smith
  January 21, 2021
• Press Release
  
  A viable vaccine for tough tumors
  November 10, 2020
• Research Spotlights
  
  i3 Center: Biomaterials to Create T Cell Immunity
  July 1, 2020